Biotech Values

[ghmm]

I can't remember who but wasn't there a case where stopping early led to insufficient longer term data? Sorry don't remember specifics.

A similar situation happened with a Pirfenidone Phase 2 study. It was stopped early because of an imbalance in acute exacerbations though it wasn't the primary end point (I think it was 12 in placebo vs. 0 or 1 in drug arm) anyway later larger trials would not repeat the finding.